October 18, 2012
is the first pharmacological agent approved for the treatment of symptomatic VMA
Conference call scheduled today at 15.00 CET (9.00 ET).
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved JETREA
(ocriplasmin) in the
for the treatment of symptomatic VMA, a progressive sight threatening condition. JETREA
is the first pharmacological agent to be approved for this indication.
The recommended dose of JETREA
is 0.125mg (0.1mL) of the diluted solution administered by intravitreal injection to the affected eye once as a single injection. JETREA
is provided as a single use glass vial containing 0.5 mg in 0.2mL solution for intravitreal injection (2.5 mg/mL).
Dr. Patrik De Haes, CEO of ThromboGenics
s FDA approval of JETREA
is a major milestone for the Company.
We are extremely pleased that we will be able to meet a major unmet clinical need in ophthalmology when we make JETREA
the first pharmacological agent for symptomatic VMA, available to the many thousands of U.S. patients who could benefit from treatment of this progressive, sight-threatening condition. We are continuing to prepare for the planned launch of JETREA
in January 2013 through our own
commercial organization. This is the biggest step in transforming ThromboGenics into a profitable biopharmaceutical company developing and commercializing innovative ophthalmic medicines.
The approval was based on the data from ThromboGenics' Phase III program where JETREA
was shown to be superior to placebo for the treatment of symptomatic VMA (26.5% versus 10.1%; p<0.01). Treatment with JETREA
was associated with some, mainly transient, ocular adverse events.
Important safety and prescribing information about JETREA
is now available at
Prof. Désiré Collen, ThromboGenics
Just over a decade ago research with autologous plasmin suggested that JETREA
, a proteolytic enzyme, could play an important role in the treatment of retinal disease. Since then ThromboGenics has successfully developed JETREA
, with the support of our shareholders and a range of collaborators, resulting in today
decision to commercialize
through its own organization means that we are now in a position to maximize returns for all of our stakeholders by successfully launching this exciting innovative product.
Dr David Boyer,
Clinical Professor of Ophthalmolo
USC/Keck School of Medicine, California
and leading investigator during ThromboGenics' clinical trials, stated: "
represents a major breakthrough for retinal specialists and their patients with symptomatic VMA. For the first time, we have a pharmacological treatment option available for many patients who would normally
only be considered surgical candidates, and that is very exciting. JETREA
represents a paradigm shift in clinical practice for the global retina community and a less invasive procedure for their patients."
Symptomatic VMA is a progressive condition that if left untreated frequently leads to retinal distortion, further deterioration in vision and has the potential to cause irreversible damage and complications. Market surveys conducted by ThromboGenics suggest that there are approximately 500,000 patients annually in the U.S. and the major markets of the EU who could potentially benefit from JETREA
A conference call for analysts, press and investors will be hosted by Dr
Patrik De Haes
, CEO of ThromboGenics, and
, CFO of ThromboGenics, today at 15.00 CET (9.00 ET).
The dial-in numbers and Participant Passcode for the call are set out below:
Belgium 0800-746-68 (Toll Free)
France 0805-630061 (Toll Free)
Germany 0800-673-7932 (Toll Free)
Ireland 01436-0959/ 1-800-930-488 (Toll Free)
Netherlands 0800-022-9132 (Toll Free)
UK +44(0)20-3003-2666/ 0808-109-0700 (Toll Free)
USA 1-866-966-5335 (Toll Free)
Participant Passcode: 4871136
We request that participants dial in 5-10 minutes prior to the start time of
). There will be a replay of the call available shortly after the call which will be accessible for seven days.
Click here for international replay numbers
followed by the Access Pin 4871136.
(ocriplasmin) is a truncated form of human plasmin that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic VMA. JETREA
is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
has been evaluated in two multi-center, randomized, double-masked Phase III trials conducted in the U.S. and
involving 652 patients with vitreomacular adhesion. Both studies met the primary endpoint of resolution of VMA at day 28.
's Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also showed that JETREA
was generally well tolerated with most adverse events being transient and mild in severity.